Steve Pfanstiel: No, I know, I think we’ve hit all the key topics there.
Scott Braunstein: Great. Let’s operator, why don’t we take the next question?
Operator: Thank you. Our next question comes from Douglas Tsao with H.C. Wainwright. Your line is open.
Douglas Tsao: Hi, thanks for taking the questions. So just maybe following-up on the commercial launch, just it sounds like you’ve seen prescription coming from 40 accounts. I’m just curious, does that represent 40 unique prescribers or do some accounts have multiple prescribers? And I’m just curious in terms of the total universe of 265 hospitals, how many have you had an engagement with so far and identified patients that they have and potentially could come on therapy at some point over the next 12 months? Thank you.
Christy Shafer: Sorry about that.
Scott Braunstein: Christy you want to kick it off? Yes.
Christy Shafer: Absolutely. Thanks for the question. So just to go back to it, 265 targets that we have balanced approach on we’ve got targets that we are mapping out between A through D, so A, B, C, D here on their level, not only influence across the country, but then number of patients that we believe that they could be potentially treating. So of those 40 accounts, I just mentioned that we have an equal number of breadth of physicians. Some accounts do have more than one physician that are treating patients. The COEs tend to have multi-disciplinary approach for CDD patients. So you’ll have several physicians there. We also have accounts that work very distinctly with not only their nurse practitioners but other ancillary staff that focuses on these patients. So we’re getting a large breadth of not only account, but physicians and healthcare providers as well. That again is encouraging and tells us that our targeting strategy has worked.
Scott Braunstein: Christy, you had the specific question from Doug, and I think I can say this, but you should clarify when we say accounts, we are saying unique physician practices, not unique physicians. Is that correct? Is that was Doug’s question?
Christy Shafer: That is correct. But not only are there unique accounts, but there are unique physicians as well.
Douglas Tsao: Okay. Thanks.
Scott Braunstein: Doug, did that get the piece through your question?
Douglas Tsao: Yes, no, no. Yes, no, it did. And I guess also I’m just curious to the extent that do you have a sense of €“ is there a spectrum and how many patients each account is treating? Or is it fairly evenly distributed?
Christy Shafer: A lot of that information €“ sorry Scott. A lot of that information we’re gathering now our MSL team did a significant amount of work early in the days to be able to map where patients are. We’re confirming a lot of that data and are covering additional patients across the United States, but right now we do not have specific amount of patients at each individual account and that that’s information that we will continue to inform.
Douglas Tsao: Okay. Great. Thank you.
Scott Braunstein: And Doug, yes, maybe I’ll just add, again, I think we could have expected early days of this launch to only come from the eight COEs that have roughly 20 to 50 patients each, right? That would’ve been very logical. And certainly one or two COEs that were big enrollers in the Phase 3 have been very big commercial supporters, but that’s the minority, not the majority. Then we have our next layer of accounts, which Christy walked you through those roughly 250 key accounts. But what’s been interesting is we’ve seen scripts not at COE, not only at those 250 accounts, but some other accounts where physicians have read the Phase 3 publication, downloaded the prior authorization form from our website and submitted it effectively spontaneously without meeting the representative.
